224 related articles for article (PubMed ID: 16361058)
1. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
[TBL] [Abstract][Full Text] [Related]
2. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
4. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
5. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
[TBL] [Abstract][Full Text] [Related]
6. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
7. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
8. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
9. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
13. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
14. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
15. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
17. Protein-Protein Interaction for the De Novo Design of Cyclin-Dependent Kinase Peptide Inhibitors.
Arumugasamy K; Tripathi SK; Singh P; Singh SK
Methods Mol Biol; 2016; 1336():59-66. PubMed ID: 26231708
[TBL] [Abstract][Full Text] [Related]
18. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors for treating cancer.
Toogood PL
Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
[TBL] [Abstract][Full Text] [Related]
20. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
